HCM
IONS icon

Highbridge Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Highbridge Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-96,060
Closed -$5.8M – 89
2019
Q4 		$5.8M Buy
+96,060
New +$5.72M 0.64% 41
2016
Q4 		– Sell
-85,500
Closed -$3.13M – 1420
2016
Q3 		$3.13M Buy
+85,500
New +$2.68M 0.05% 352
2015
Q3 		– Sell
-12,350
Closed -$711K – 1685
2015
Q2 		$711K Buy
+12,350
New +$785K 0.01% 840

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's IONS Position: Q1 2020 in Review

Highbridge Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2020, closing a stake of 96,060 shares — an estimated $5.8M sold.

Highbridge Capital Management first reported a position in IONS in Q2 2015 and held it in 3 quarters. The position peaked at $5.8M in Q4 2019. 363 funds tracked by Wall St. Rank hold IONS as of Q1 2020.

  • Highbridge Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Highbridge Capital Management sold 96,060 Ionis Pharmaceuticals shares in Q1 2020, an estimated $5.8M.
  • Highbridge Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Highbridge Capital Management's Ionis Pharmaceuticals position peaked at $5.8M in Q4 2019.
  • 363 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2020.

Based on Highbridge Capital Management's 13F filing for Q1 2020, filed 15 May 2020.